Mira Pharmaceuticals (MIRA) Change in Accured Expenses (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Change in Accured Expenses of $45278.0 for Q4 2025, up 121.11% sequentially from -$214533.0 in Q3 2025, and up 48.38% YoY from $30515.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Change in Accured Expenses (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 4 years of Change in Accured Expenses data on file, last reported at $45278.0 in Q4 2025.
- Quarterly Change in Accured Expenses rose 48.38% year-over-year to $45278.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$594146.0 (down 421.53% YoY) and the FY2025 annual result came in at -$594146.0, down 421.53% from the prior year.
- Change in Accured Expenses grew to $45278.0 in Q4 2025 per MIRA's latest filing, from -$214533.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $347684.0 in Q3 2022, with the low at -$617176.0 in Q1 2025.
- Average Change in Accured Expenses over 4 years is -$19915.7, with a median of $71487.5 recorded in 2024.
- Year-over-year, Change in Accured Expenses soared 132.76% in 2024 and tumbled 731.72% in 2025.
- Mira Pharmaceuticals' Change in Accured Expenses stood at $172381.0 in 2022, then sank by 239.81% to -$241008.0 in 2023, then soared by 112.66% to $30515.0 in 2024, then soared by 48.38% to $45278.0 in 2025.
- Business Quant data shows MIRA's Change in Accured Expenses at $45278.0 in Q4 2025, -$214533.0 in Q3 2025, and $192285.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -629.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -1.59 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | 45,278.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,278.00 |
| Dec 31, 2025 | 45,278.00 |
| Sep 30, 2025 | -214,533.00 |
| Sep 30, 2025 | -214,533.00 |
| Jun 30, 2025 | 192,285.00 |
| Jun 30, 2025 | 192,285.00 |
| Mar 31, 2025 | -617,176.00 |
| Mar 31, 2025 | -617,176.00 |
| Dec 31, 2024 | 30,515.00 |
| Dec 31, 2024 | 30,515.00 |
| Sep 30, 2024 | -89,306.00 |
| Sep 30, 2024 | -89,306.00 |
| Jun 30, 2024 | 145,879.00 |
| Jun 30, 2024 | 145,879.00 |
| Mar 31, 2024 | 97,697.00 |
| Mar 31, 2024 | 97,697.00 |
| Dec 31, 2023 | -241,008.00 |
| Dec 31, 2023 | -241,008.00 |
| Sep 30, 2023 | 120,467.00 |
| Sep 30, 2023 | 120,467.00 |